Table 2.

Patients with advanced CTCL and lack of short-term clinical responses on extracorporeal photopheresis momotherapgy (Group2)

Patient/age (years)/sex	DX	TNBM	Months	Response	%SC	SC/mm3	%CD4/8/7	CD4/8	CD4P7N/mm3†	LDH
13/44/F*	SS	T4N1B2	0		70	2010	79/11/41	7.2	41	251
			3	W	75	2772	77/12/46	6.4	<6	178
			6	NR	55	2884	78/10/28	7.8	28	213
			>6	IFN-α: NR
14/66/M*	SS	T4N3B2	0		57	614	85/5/87	17.0	–	225
			3	MR	68	799	86/4/85	21.5	–	224
			6	NR	<6	149	–	–	–	213
15/69/M*	SS	T4NXB2	0		52	860	88/3/17	29.3	1207	198
			3	NR	67	965	89/3/18	29.7	1051	175
			6	NR	58	438	79/4/28	19.8	416	204
			>6	IFN-α: MR
16/67/M	SS	T4N3B2	0		52	2677	92/3/94	30.7	–	300
			3	PR	47	2386	94/2/47	47.0	–	385
			6	W	37	2174	95/3/95	31.7	–	347
			>6	IFN-α: NR
17/50/M	MF	T3(2)N1B1	0		13	496	38/31/74	1.2	–	161
			3	W	36	242	43/27/75	1.6	–	184
			6	DP	16	188	–	–	–	200
18/72/F	SS	T4NXB2	0		54	3558	89/6/12	14.8	5468	216
			3	NR	29	2212	87/7/14	12.4	6101	238
			6	W	52	2777	86/7/11	12.3	4380	293
			>6	IFN-α: NR
19/61/M	MF	T2NXB2	0		42	511	77/2/69	38.5	–	256
			3	W	56	511	72/2/80	36.0	–	275
			6	NR	43	636	75/2/84	37.5	–	230
			>6	IFN-α: PR
20/80/M	SS	T4N3B2	0		85	5039	88/1/77	88.0	–	602
			3	NR	80	7410	97/1/80	97.0	–	578
			6	NR	95	5045	98/0.1/79	980.0	–	486
21/73/F	SS	T4NXB2	0		68	3225	79/10/32	7.9	1945	248
			3	NR	76	5194	83/8/27	10.4	4305	250
			6	NR	84	4287	86/9/25	9.6	3471	285

^*Patients 13–15 previously reported as cases 8, 9, and 17, respectively (29).

See footnote of Table 1 for definitions.